Debiopharm Innovation Fund: the New Name and Investment Strategy of Debiopharm Diagnostics

Tuesday, March 7, 2017 Research News J E 4
Change in name reflects new strategy to invest in smart data, therapeutics and diagnostics

LAUSANNE, Switzerland, March 7, 2017 /PRNewswire/ --

Debiopharm Diagnostics SA, the strategic investment fund of Debiopharm Group (, announced its new strategy and the change of name to Debiopharm Innovation Fund SA effective today. With the aim of speeding up innovations that radically improve therapeutic development and treatment of patients, the company is broadening its investment scope beyond diagnostics to include smart data and therapeutics.

Debiopharm Innovation Fund's objective is to make strategic investments related to Debiopharm Group's areas of interest: oncology and infectious disease. The fund invests in young companies developing smart data, therapeutic, and diagnostic solutions that will have an impact on patients. Typically the fund invests in therapeutic startups at the preclinical stage, in diagnostics at the development stage, and in smart data at the early commercialization stage.

"We are excited to build a bold portfolio of companies that, for example, use the massively increasing volumes of healthcare data and artificial intelligence to create therapeutics or actionable results for clinicians," said Tanja Dowe, Head of Debiopharm Innovation Fund. She continued, "Our strategic fund's vision is to provide Debiopharm Group with an insight to the future through investments in innovative companies that change the way we develop drugs and treat patients."

About Debiopharm Innovation Fund SA 

Part of Debiopharm Group™, a Swiss-headquartered global biopharmaceutical group of five companies, Debiopharm Innovation Fund's mission is to invest in companies developing innovative therapeutics, diagnostics and smart data solutions that change the way we develop drugs and treat patients. Since 2008, the company has invested nearly USD 100 million and led 10 out of the 14 last investment rounds in its portfolio company.

For more information, please visit

We are on Twitter. Follow us @DebiopharmNews at

Debiopharm Innovation Fund SA Contact Christelle Tur Communication Coordinator Tel: +41(0)21-321-01-11

SOURCE Debiopharm International SA



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
How These Biotech Stocks are Faring? -- Corbus Pha...
Novasep Appoints Xavier de Saint Guilhem as Chief ...